Chemotherapy Induced Peripheral Neuropathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Chemotherapy Induced Peripheral Neuropathy Pipeline Drugs Market Overview

The Chemotherapy-induced Peripheral Neuropathy – Drugs in Development research report provides a comprehensive overview on the therapeutics under development for Chemotherapy-induced Peripheral Neuropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.  The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.  Additionally, the report provides an overview of key players involved in therapeutic development for Chemotherapy-induced Peripheral Neuropathy and features dormant and discontinued projects.

Key Targets in the Chemotherapy-Induced Peripheral Neuropathy Pipeline Drugs Market

In the Chemotherapy-Induced Peripheral Neuropathy pipeline drugs market the key targets are Cannabinoid Receptor 2, Cannabinoid Receptor 1, Glutamate Ionotropic Receptor NMDA Type Subunit, Histone Deacetylase 6, Sodium Channel Protein Type 9 Subunit Alpha, DNA (Apurinic or Apyrimidinic Site) Lyase, Free Radical, Muscarinic Acetylcholine Receptor M1, Prostaglandin G/H Synthase 1, and Prostaglandin G/H Synthase 2.

CIPN Pipeline Drugs Market, by Targets

For more target insights, download a free report sample

Key MoA in the Chemotherapy-Induced Peripheral Neuropathy Pipeline Drugs Market

Cannabinoid Receptor 2 Agonist has the highest number of pipeline products followed by Cannabinoid Receptor 1 Agonist, Histone Deacetylase 6 Inhibitor, DNA (Apurinic or Apyrimidinic Site) Lyase Inhibitor, Free Radical Scavenger, Glutamate Ionotropic Receptor NMDA Type Subunit Antagonist, Muscarinic Acetylcholine Receptor M1 Antagonist, Prostaglandin G/H Synthase 1 Inhibitor, Prostaglandin G/H Synthase 2 Inhibitor, and Sodium Channel Protein Type 9 Subunit Alpha Inhibitor.

Chemotherapy-Induced Peripheral Neuropathy Pipeline Drugs Market, by MoA

To get more insights on key MoA, download a free sample report

Chemotherapy-Induced Peripheral Neuropathy Pipeline Drugs Market Segmentation by RoA

The key routes of administration in the CIPN pipeline drugs market are Oral, Topical, Intravenous, Inhalational, Intramuscular, Intravenous Bolus, Intravenous Drip, Subcutaneous, Intradermal, Intravitreal. Oral has the maximum number of pipeline products.

Chemotherapy-Induced Peripheral Neuropathy Pipeline Drugs Market Analysis, by RoA

To get more insights on key RoA, download a free sample report

Key Molecule Types in the Chemotherapy-Induced Peripheral Neuropathy Pipeline Drugs Market

The key molecule types in the Chemotherapy-Induced Peripheral Neuropathy pipeline drugs market are Small Molecule, Recombinant Protein, Monoclonal Antibody, Antisense Oligonucleotide, Biologic, Fusion Protein, Gene Therapy, Protein, Recombinant Enzyme, and Synthetic Peptide.

Chemotherapy-Induced Peripheral Neuropathy Pipeline Drugs Market, by Molecule Type

To get more insights on key molecule types, download a free sample report

Major Companies in the Chemotherapy-Induced Peripheral Neuropathy Pipeline Drugs Market

The major companies in the CIPN pipeline drugs market are Apexian Pharmaceuticals Inc, Aphios Corp, Asahi Kasei Pharma Corp, Bristol-Myers Squibb Co, Regulonix LLC, Winsantor Inc, Abalone Bio Inc, Achelios Therapeutics Inc, Algenis, and Algo Therapeutix SAS.

Chemotherapy-Induced Peripheral Neuropathy Pipeline Drugs Market, by Major Companies

For more company insights, download a free sample report

Chemotherapy-Induced Peripheral Neuropathy Pipeline Drugs Market Overview

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Chemotherapy-Induced Peripheral Neuropathy
• The pipeline guide reviews pipeline therapeutics for Chemotherapy-Induced Peripheral Neuropathy by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Chemotherapy-Induced Peripheral Neuropathy therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Chemotherapy-Induced Peripheral Neuropathy therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews the latest news related to pipeline therapeutics for Chemotherapy-Induced Peripheral Neuropathy

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with a potentially strong product portfolio and create effective counter strategies to gain a competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Chemotherapy-Induced Peripheral Neuropathy
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Chemotherapy-Induced Peripheral Neuropathy pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.